- Home
- PRLD vs EDIT Comparison
PRLD vs EDIT Comparison
Compare PRLD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | EDIT |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 206.0M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PRLD | EDIT |
|---|---|---|
| Price | $3.65 | $2.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.67 | ★ $4.92 |
| AVG Volume (30 Days) | 197.9K | ★ 1.6M |
| Earning Date | 03-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | $12,140,000.00 | ★ $31,937,000.00 |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 73.43 | ★ 132.64 |
| 52 Week Low | $0.61 | $0.91 |
| 52 Week High | $4.19 | $4.54 |
Technical Indicators
Market Signals| Indicator | PRLD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 63.48 |
| Support Level | $1.02 | $2.42 |
| Resistance Level | $4.10 | $2.76 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 91.38 | 85.48 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.